Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.51 |
| ▸ | PPARA | Q07869 | 7/20 | 0.51 |
| ▸ | KLK7 | P49862 | 4/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL359777 | 1.00 | PPARG (0.51) | PPARGPPARAKLK7CNR1ACP3 | |
| SCHEMBL9554385 | 0.84 | SRR (0.57) | PPARGPPARAKLK7ACESRR | |
| SCHEMBL359759 | 0.83 | KLK7 (0.57) | PPARGPPARAKLK7CHRM2CHRM4 | |
| SCHEMBL359760 | 0.83 | KLK7 (0.57) | PPARGPPARAKLK7CHRM2CHRM4 | |
| SCHEMBL360673 | 0.80 | KLK7 (0.59) | PPARGKLK7CHRM2CHRM4CHRM1 | |
| SCHEMBL360674 | 0.80 | KLK7 (0.59) | PPARGKLK7CHRM2CHRM4CHRM1 | |
| SCHEMBL360653 | 0.79 | KLK7 (0.68) | KLK7CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL360652 | 0.79 | KLK7 (0.68) | KLK7CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7344014 | 0.79 | PPARG (0.55) | PPARGPPARAACESRR | |
| SCHEMBL7344016 | 0.79 | PPARG (0.55) | PPARGPPARAACESRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407447-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER | TOKYO UNIV OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2018-04-18 | — | — | EP | disclosed |
| US-8552215-B2 | Method for producing optically active 2-hydroxy ester and novel intermediate compound | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2407447-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | Tokyo University Of Science Educational Foundation Administrative Organization (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319650-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | TOKYO UNIVERSITY OF SCIENCE EDUCATIONAL FOUNDATION ADMINISTRATIVE ORGANIZATION (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319650-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE 2-HYDROXY ESTER AND NOVEL INTERMEDIATE COMPOUND | CA7, HAO2, HACL2 | PPARG 1463/4885PPARA 1330/4885KLK7 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.